Sherbrooke Park Advisers LLC Gilead Sciences, Inc. Transaction History

Sherbrooke Park Advisers LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$63.15 - $72.88 $495,980 - $572,399	-7,854 Reduced 44.6%	9,754 $669 Million
Q1 2024 May 15, 2024	BUY	$71.58 - $87.29 $1.26 Million - $1.54 Million	17,608 New	17,608 $1.29 Billion
Q3 2023 Nov 14, 2023	BUY	$73.94 - $80.67 $933,566 - $1.02 Million	12,626 Added 133.48%	22,085 $1.66 Billion
Q2 2023 Aug 14, 2023	BUY	$76.01 - $86.7 $718,978 - $820,095	9,459 New	9,459 $729 Million

1,927

994M

10.5M

9.75M

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $116B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

Get notified when there are updates to the investment portfolio of Sherbrooke Park Advisers LLC, based on Form 13F filings with the SEC.

Stay updated on Sherbrooke Park Advisers LLC with notifications on news.